K4 Elite logo K4 Elite
Home / Peptide Library / Omberacetam (Noopept)
Well Researched

Omberacetam (Noopept)

Cognitive & Neurological · ['Noopept', 'GVS-111', 'SGS-111', 'N-phenylacetyl-L-prolylglycine ethyl ester']

A synthetic proline-containing dipeptide nootropic developed in Russia as a cyclic analog of piracetam, studied in rodent and in vitro models for neuroprotective, BDNF/NGF-modulating, and memory-related effects.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Molecular Formula
C17H22N2O4
Molecular Weight
318.4 g/mol
PubChem
CID 180496 ↗
Research Level
Well Researched
Browse the store →
Omberacetam (Noopept) chemical structure

Omberacetam, widely known as Noopept (development codes GVS-111 and SGS-111), is a synthetic dipeptide developed at the Zakusov Institute of Pharmacology in Russia. It is a proline-containing analog conceptually related to the racetam family, and it is one of the more extensively studied compounds in this reference batch, with a substantial body of Russian preclinical and clinical literature.

Chemically it is N-phenylacetyl-L-prolylglycine ethyl ester (PubChem CID 180496), with molecular formula C17H22N2O4 and a molecular weight of about 318.4 g/mol. It is often described as orally active in the animal literature.

The material referenced here is discussed strictly on the basis of published research. It is provided for reference and research use only and is not a recommendation for consumption.

In rodent and in vitro studies, Noopept has been reported to act as a prodrug that yields the endogenous cyclic dipeptide cycloprolylglycine (cyclic glycine-proline), an AMPA-receptor modulator. Reported activities include upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) gene expression, positive modulation of AMPA-receptor currents, and reduction of glutamate excitotoxicity.

Additional targets described in the literature include alpha-7 nicotinic acetylcholine receptor modulation and HIF-1 pathway activation, along with antioxidant and anti-inflammatory effects observed in cell and animal models. These are mechanistic findings from experimental systems, not established clinical outcomes.

  • Neurotrophin (BDNF/NGF) expression: Rodent studies reporting increased hippocampal BDNF and NGF gene expression after administration.
  • AMPA-receptor modulation: In vitro electrophysiology and studies of the cycloprolylglycine metabolite as a positive AMPA modulator.
  • Neuroprotection / anti-ischemia: Animal models of hypoxia and oxidative stress examining protective effects.
  • Learning and memory paradigms: Rodent behavioral studies (passive avoidance, Morris water maze) evaluating memory endpoints.
  • Clinical cognitive research: Russian clinical studies in post-stroke and mild cognitive impairment populations.
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Ostrovskaya et al. (cycloprolylglycine metabolite studies): Reported that Noopept generates the endogenous dipeptide cycloprolylglycine and characterized its AMPA-modulating and neuroprotective activity in rodent and in vitro systems. Reported for reference only.

Neznamov & Teleshova, clinical study (2009): A comparative clinical study in patients with mild cognitive disorders of vascular and post-traumatic origin reported cognitive and asthenic-symptom endpoints for Noopept versus piracetam. Described here for information only, not as a usage guideline.

Preclinical antioxidant/BDNF reports: Multiple rodent studies described increased neurotrophin expression and reduced markers of oxidative stress following administration. Any doses reported in these animal studies are experimental parameters, not recommendations.

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

Cyclic glycine-proline (cGP)Neutral
cGP (cycloprolylglycine) is described as an active metabolite of Noopept, so their pharmacology overlaps in the research literature.
Piracetam and other racetamsCompatible
Structurally related nootropics used as comparators in clinical and preclinical studies.
Cholinergic agentsSynergistic
Alpha-7 nicotinic modulation reported for Noopept may theoretically interact with cholinergic tool compounds in research settings.
CNS depressants / sedativesCaution
Combined central nervous system effects are not well characterized; a general caution noted in the literature.

References are being compiled for this entry.

What kind of molecule is Noopept?
It is a synthetic proline-containing dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) developed as a nootropic and often described as a cyclic analog related to piracetam.
What is cycloprolylglycine and how does it relate to Noopept?
In the research literature Noopept is described as a prodrug that generates cycloprolylglycine (cyclic glycine-proline), an endogenous AMPA-receptor modulator thought to contribute to its reported activity.
What targets does Noopept engage in studies?
Reported targets in rodent and in vitro work include BDNF/NGF upregulation, AMPA-receptor modulation, alpha-7 nicotinic receptors, and HIF-1 activation, along with antioxidant effects.
Is there human data?
There is a body of Russian clinical literature in cognitive-impairment populations, but this reference does not summarize efficacy claims and does not provide dosing.
Can I use Noopept as a supplement?
No. This entry is for research and reference only. Noopept is not an approved drug or dietary supplement in many jurisdictions, and nothing here is medical advice or a usage recommendation.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.